Jae Hun Ahn

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial

J.L. Lee, M.K. Kim, Inkeun Park et al. · Annals of Oncology · 2015 · 108 citations

Medicine, Oncology, Pharmacotherapy +10

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma

Youngil Koh, Ho Yeong Lim, Jae Hun Ahn et al. · Annals of Oncology · 2012 · 86 citations · Full text

Medicine, Nephrology, Oncology +11

The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction

Changhee Yoo, Jeong Eun Kim, J.-L. Lee et al. · Japanese Journal of Clinical Oncology · 2010 · 86 citations

Medicine, Oncology, Pharmacology +14

Sunitinib, a Novel Therapy for Anthracycline- and Cisplatin-refractory Malignant Pheochromocytoma

K.-S. Park, J.-L. Lee, J.-L. Lee et al. · Japanese Journal of Clinical Oncology · 2009 · 35 citations · Full text

Medicine, Endocrinology, Oncology +17

Updated Longitudinal Data on Acute Exacerbation of Chronic Hepatitis B in Patients With Breast Cancer Receiving Anthracycline-based Adjuvant Chemotherapy: Therapeutic vs. Pre-emptive Use of Lamivudine

Byeong Seok Sohn, Jae Hun Ahn, K.H. Jung et al. · Japanese Journal of Clinical Oncology · 2011 · 13 citations

Medicine, Oncology, Pharmacotherapy +17